Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma
Genes, Chromosomes and Cancer · 2025
DOI: 10.1002/gcc.70076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, Chromosomes and Cancer, 2025. Verfasst von Yamato Suemitsu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Chondrosarcoma, Neoplasms, Connective and Soft Tissue. Die Arbeit nennt 41 Literaturangaben. Gefördert von: NIH HHS, Cycle for Survival, Kristin Ann Carr Foundation.
Abstract (Originalsprache)
Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm of uncertain histogenesis, characterized by recurrent gene fusions involving NR4A3 with various gene partners ( EWSR1 , TAF15, FUS , etc.). Although the impact of fusion variants has been linked to histology and prognosis, no study to date has comprehensively investigated the incidence and spectrum of secondary genetic alterations (SGAs) in EMC with regard to their association with fusion type and clinical impact. Our molecular database was searched for EMC tested on a hybridization capture‐based targeted matched tumor‐normal DNA NGS assay (MSK‐IMPACT, 341‐505 gene panel). All tumors had their fusion subtype confirmed either by Archer FusionPlex and/or fluorescence in situ hybridization (FISH). Clinicopathologic data was reviewed. Eighteen EMC patients (20 samples) were selected, with a mean age of 61 years and a male: female ratio of 5:1. By molecular testing, the most common NR4A3 fusion subtype involved EWSR1 (14/18, 78%), while two cases involved TAF15 gene partner, and one each TCF12 and FUS genes, respectively. All cases showed a low tumor mutation burden (TMB) (0–2, mean 0.83). Two‐thirds of cases had concurrent SGAs, while the remaining showed only the driver NR4A3 fusion (0–8, mean 1.67 mut/case). Among the detected SGAs, only TP53 alterations were recurrent, seen in 2 cases with EWSR1::NR4A3 and TAF15::NR4A3 fusions, respectively. Other non‐recurrent alterations involved CDKN1B , TERT , and MET genes, among others. Non‐ EWSR1 fusion variant tumors showed a tendency for a higher number of SGAs compared to EWSR1 ‐rearranged tumors (mean 2.75 versus 1.36 mut/case). Patients with ≥ 1 SGA showed lower disease‐free survival (DFS) ( p = 0.022) and poor overall survival (OS) ( p = 0.014), while no statistically significant correlation was detected between OS and fusion subtypes. Most patients (83%) developed distant metastases, which did not correlate with the SGA status. This is the first study addressing the genomic landscape in EMC with regard to prognostication beyond fusion subtypes and histology. Similar to other translocation‐associated sarcomas, the number of co‐occurring SGAs in EMC is low; however, when present, they are associated with worse survival. Although a higher number of SGAs showed a trend to be associated with non‐ EWSR1 fusion variants, larger multi‐institutional studies are needed to further evaluate the correlation between fusion variants with SGAs and survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Hsin-Yi Chang, Josephine K Dermawan, Cristina R Antonescu
Förderung
- NIH HHS
- Cycle for Survival
- Kristin Ann Carr Foundation
- National Institutes of Health
Zitieren
APA
Suemitsu, Y., Chang, H. Y., Saoud, C., Dermawan, J. K., Hameed, M., Singer, S., Tap, W. D., & Antonescu, C. R. (2025). Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma. Genes, Chromosomes and Cancer. https://doi.org/10.1002/gcc.70076
Vancouver
Suemitsu Y, Chang HY, Saoud C, Dermawan JK, Hameed M, Singer S, et al. Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma. Genes, Chromosomes and Cancer. 2025. doi:10.1002/gcc.70076
BibTeX
@article{Suemitsu2025,
author = {Suemitsu, Yamato and Chang, Hsin-Yi and Saoud, Carla and Dermawan, Josephine K and Hameed, Meera and Singer, Samuel and Tap, William D and Antonescu, Cristina R},
title = {Secondary Genetic Alterations in Extraskeletal Myxoid Chondrosarcoma},
journal = {Genes, Chromosomes and Cancer},
year = {2025},
doi = {10.1002/gcc.70076}
}
EUVIMED